Literature DB >> 29920840

Targeted resequencing reveals genetic risks in patients with sporadic idiopathic pulmonary fibrosis.

Yanhan Deng1, Zongzhe Li2, Juan Liu1, Zheng Wang3, Yanyan Cao2, Yong Mou1, Bohua Fu1, Biwen Mo4, Jianghong Wei4, Zhenshun Cheng5, Liman Luo6, Jingping Li7, Ying Shu7, Xiaomei Wang8, Guangwei Luo9, Shuo Yang9, Yingnan Wang10, Jing Zhu10, Jingping Yang11, Ming Wu11, Xuyan Xu12, Renying Ge12, Xueqin Chen13, Qingzhen Peng14, Guang Wei14, Yaqing Li15, Hua Yang16, Shirong Fang16, Xiaoju Zhang3, Weining Xiong1.   

Abstract

Idiopathic pulmonary fibrosis (IPF) is a genetic heterogeneous disease with high mortality and poor prognosis. However, a large fraction of genetic cause remains unexplained, especially in sporadic IPF (∼80% IPF). By systemically reviewing related literature and potential pathogenic pathways, 92 potentially IPF-related genes were selected and sequenced in genomic DNAs from 253 sporadic IPF patients and 125 matched health controls using targeted massively parallel next-generation sequencing. The identified risk variants were confirmed by Sanger sequencing. We identified two pathogenic and 10 loss-of-function (LOF) candidate variants, accounting for 4.74% (12 out of 253) of all the IPF cases. In burden tests, rare missense variants in three genes (CSF3R, DSP, and LAMA3) were identified that have a statistically significant relationship with IPF. Four common SNPs (rs3737002, rs2296160, rs1800470, and rs35705950) were observed to be statistically associated with increased risk of IPF. In the cumulative risk model, high risk subjects had 3.47-fold (95%CI: 2.07-5.81, P = 2.34 × 10-6 ) risk of developing IPF compared with low risk subjects. We drafted a comprehensive map of genetic risks (including both rare and common candidate variants) in patients with IPF, which could provide insights to help in understanding mechanisms, providing genetic diagnosis, and predicting risk for IPF.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  common SNP; genetic factors; idiopathic pulmonary fibrosis; next-generation sequencing; risk stratification

Mesh:

Substances:

Year:  2018        PMID: 29920840     DOI: 10.1002/humu.23566

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  13 in total

1.  Scutellarein inhibits BLM-mediated pulmonary fibrosis by affecting fibroblast differentiation, proliferation, and apoptosis.

Authors:  Kang Miao; Ting Pan; Yong Mou; Lei Zhang; Weining Xiong; Yongjian Xu; Jun Yu; Yi Wang
Journal:  Ther Adv Chronic Dis       Date:  2020-07-30       Impact factor: 5.091

2.  Targeted resequencing showing novel common and rare genetic variants increases the risk of asthma in the Chinese Han population.

Authors:  Juan Liu; Yanhan Deng; Bo Yu; Biwen Mo; Liman Luo; Jingping Yang; Xiaoju Zhang; Zheng Wang; Yingnan Wang; Jing Zhu; Hua Yang; Shirong Fang; Zhenshun Cheng; Jingping Li; Ying Shu; Guangwei Luo; Weining Xiong; Jianghong Wei; Zongzhe Li
Journal:  J Clin Lab Anal       Date:  2021-05-09       Impact factor: 2.352

3.  A nonsynonymous polymorphism (rs117179004, T392M) of hyaluronidase 1 (HYAL1) is associated with increased risk of idiopathic pulmonary fibrosis in Southern Han Chinese.

Authors:  Juan Liu; Yanhan Deng; Zheng Wang; Biwen Mo; Jianghong Wei; Zhenshun Cheng; Qingzhen Peng; Guang Wei; Jingping Li; Ying Shu; Hua Yang; Shirong Fang; Guangwei Luo; Shuo Yang; Yingnan Wang; Jing Zhu; Jingping Yang; Ming Wu; Xuyan Xu; Renying Ge; Xiaoju Zhang; Weining Xiong; Xiaomei Wang; Zongzhe Li
Journal:  J Clin Lab Anal       Date:  2021-05-04       Impact factor: 2.352

4.  Identification and functional characterization of a novel surfactant protein A2 mutation (p.N207Y) in a Chinese family with idiopathic pulmonary fibrosis.

Authors:  Lv Liu; Jieli Qin; Ting Guo; Ping Chen; Ruoyun Ouyang; Hong Peng; Hong Luo
Journal:  Mol Genet Genomic Med       Date:  2020-06-30       Impact factor: 2.183

5.  Integration of SNP Disease Association, eQTL, and Enrichment Analyses to Identify Risk SNPs and Susceptibility Genes in Chronic Obstructive Pulmonary Disease.

Authors:  Yang Liu; Kun Huang; Yahui Wang; Erqiang Hu; Benliang Wei; Zhaona Song; Yuqing Zou; Luanfeng Ge; Lina Chen; Wan Li
Journal:  Biomed Res Int       Date:  2020-12-29       Impact factor: 3.411

6.  Hermansky-Pudlak syndrome: Mutation update.

Authors:  Marjan Huizing; May C V Malicdan; Jennifer A Wang; Hadass Pri-Chen; Richard A Hess; Roxanne Fischer; Kevin J O'Brien; Melissa A Merideth; William A Gahl; Bernadette R Gochuico
Journal:  Hum Mutat       Date:  2020-01-23       Impact factor: 4.700

Review 7.  Macrophages: friend or foe in idiopathic pulmonary fibrosis?

Authors:  Lei Zhang; Yi Wang; Guorao Wu; Weining Xiong; Weikuan Gu; Cong-Yi Wang
Journal:  Respir Res       Date:  2018-09-06

8.  Genome-Wide Association Study of Susceptibility to Idiopathic Pulmonary Fibrosis.

Authors:  Richard J Allen; Beatriz Guillen-Guio; Justin M Oldham; Shwu-Fan Ma; Amy Dressen; Megan L Paynton; Luke M Kraven; Ma'en Obeidat; Xuan Li; Michael Ng; Rebecca Braybrooke; Maria Molina-Molina; Brian D Hobbs; Rachel K Putman; Phuwanat Sakornsakolpat; Helen L Booth; William A Fahy; Simon P Hart; Mike R Hill; Nik Hirani; Richard B Hubbard; Robin J McAnulty; Ann B Millar; Vidyia Navaratnam; Eunice Oballa; Helen Parfrey; Gauri Saini; Moira K B Whyte; Yingze Zhang; Naftali Kaminski; Ayodeji Adegunsoye; Mary E Strek; Margaret Neighbors; Xuting R Sheng; Gunnar Gudmundsson; Vilmundur Gudnason; Hiroto Hatabu; David J Lederer; Ani Manichaikul; John D Newell; George T O'Connor; Victor E Ortega; Hanfei Xu; Tasha E Fingerlin; Yohan Bossé; Ke Hao; Philippe Joubert; David C Nickle; Don D Sin; Wim Timens; Dominic Furniss; Andrew P Morris; Krina T Zondervan; Ian P Hall; Ian Sayers; Martin D Tobin; Toby M Maher; Michael H Cho; Gary M Hunninghake; David A Schwartz; Brian L Yaspan; Philip L Molyneaux; Carlos Flores; Imre Noth; R Gisli Jenkins; Louise V Wain
Journal:  Am J Respir Crit Care Med       Date:  2020-03-01       Impact factor: 30.528

9.  Klotho antagonizes pulmonary fibrosis through suppressing pulmonary fibroblasts activation, migration, and extracellular matrix production: a therapeutic implication for idiopathic pulmonary fibrosis.

Authors:  Qiqing Huang; Yan Chen; Shaoran Shen; Yuanyuan Wang; Liya Liu; Shuangshuang Wu; Wei Xu; Weihong Zhao; Mingyan Lin; Jianqing Wu
Journal:  Aging (Albany NY)       Date:  2020-04-03       Impact factor: 5.682

10.  Complement Receptor 1 (CR1, CD35) Polymorphisms and Soluble CR1: A Proposed Anti-inflammatory Role to Quench the Fire of "Fogo Selvagem" Pemphigus Foliaceus.

Authors:  Luana Caroline Oliveira; Gabriela Canalli Kretzschmar; Andressa Cristina Moraes Dos Santos; Carolina Maciel Camargo; Renato Mitsunori Nisihara; Ticiana Della Justina Farias; Andre Franke; Michael Wittig; Enno Schmidt; Hauke Busch; Maria Luiza Petzl-Erler; Angelica Beate Winter Boldt
Journal:  Front Immunol       Date:  2019-11-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.